A Single-arm, Open-label, Phase 1 Study Evaluating the Safety, Efficacy, and Cellular Kinetics/Pharmacodynamics of ALLO-715 and ALLO-647 to Evaluate an Anti-BMCA Allogeneic CAR T Cell Therapy with or without Nirogacestat in Patients with Relapsed/Ref

Protocol No

ALLOGENE-ALLO-715-101-RRMM

Principal Investigator

Meera Mohan

Phase

I

Summary

To test the safety of ALLO-715 in combination with ALLO-647 and to determine the safe dose of ALLO-715 following lymphodepletion with ALLO-647.

Description

Phase 1 Study of ALLO-715, an antiBCMA Allo CAR-T cell therapy for pt with rrMM

Participating Institutions

Froedtert Hospital

Status

OPEN TO ACCRUAL

Sub Category

ClinicalTrials.gov

go to website

A Single-arm, Open-label, Phase 1 Study Evaluating the Safety, Efficacy, and Cellular Kinetics/Pharmacodynamics of ALLO-715 and ALLO-647 to Evaluate an Anti-BMCA Allogeneic CAR T Cell Therapy with or without Nirogacestat in Patients with Relapsed/Refractory Multiple Myeloma